Company signs a worldwide licensing agreement with Pherin Pharmaceuticals for the development and commercialization of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder Untreated social anxiety disorder has a significant impact on a person’s overall … Continue reading →